U.S. Alzheimer’s Drugs MarketU.S. Alzheimer’s Drugs Market Charting Growth Trajectories: Analysis and Forecasts 2024-2032
U.S. Alzheimer’s Drugs Market by Drug Class (Cholinesterase Inhibitors, NMDA Receptor Antagonist, Combination Drugs, Others), by Application (Disease Progression, Symptom Management), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy & Drug Stores, Online Pharmacy), by Forecast 2024-2032
Base Year: 2023
120 Pages
U.S. Alzheimer’s Drugs Market Charting Growth Trajectories: Analysis and Forecasts 2024-2032
Key Insights
The U.S. Alzheimer's drugs market was valued at $3.52 billion in 2022 and is projected to grow to $5.21 billion by 2030, with a compound annual growth rate (CAGR) of 5.1%. Alzheimer’s drugs are medications that aim to eliminate symptoms while slowing the progress of Alzheimer’s disease, a condition affecting the brain and degrade cognitive function and memory. Two broad divisions can be outlined here: acetylcholinesterase inhibitors (donepezil, rivastigmine) and N-methyl-D-aspartate receptor antagonists (memantine). With cholinesterase inhibitors, neurotransmitters, which are thought to be fundamental in memory and learning, are boosted. NMDA regulates glutamate activity and glutamate is involved in brain cell death. This particular medication helps reduce the symptoms of comatose by improving cognitive function, daily living activities, and behavior in patients. On the one hand, they are not miracle drugs that scare the disease, but they can at least alleviate symptoms. In the USA, the most demanded therapeutic for Alzheimer’s is placed because of the aging people and their impacted awareness of this disease.
U.S. Alzheimer’s Drugs Trends
- Growing prevalence of Alzheimer's disease
- Rising geriatric population
- Increasing awareness about Alzheimer's disease
- Technological advancements in drug development
Driving Forces: What's Propelling the U.S. Alzheimer’s Drugs Market
- Government initiatives and funding for Alzheimer's research
- Increasing collaborations between pharmaceutical companies and research institutions
- Growing demand for effective treatments for Alzheimer's disease
Challenges and Restraints in U.S. Alzheimer’s Drugs Market
- Lack of effective cure for Alzheimer's disease
- High cost of Alzheimer's drugs
- Side effects associated with Alzheimer's drugs
Emerging Trends in U.S. Alzheimer’s Drugs
- Development of novel therapies targeting different aspects of Alzheimer's disease
- Use of artificial intelligence and machine learning in drug discovery
- Personalized medicine approaches tailored to individual patients
Growth Catalysts in the U.S. Alzheimer’s Drugs Industry
- Increasing investment in research and development of new drugs
- Development of disease-modifying therapies
- Expansion of access to Alzheimer's drugs through insurance coverage
Market Segmentation: U.S. Alzheimer’s Drugs Analysis
Leading Players in the U.S. Alzheimer’s Drugs Market
Significant Developments in the U.S. Alzheimer’s Drugs Sector
- November 2023: Halozyme Therapeutics, Inc. and Acumen Pharmaceuticals announced a collaboration and non-exclusive license agreement for the ENHANCE technology in Alzheimer's Disease.
- January 2023: H. Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd. announced that the U.S. FDA has accepted a supplemental New Drug Application (sNDA) for brexpiprazole that can be used to treat agitation associated with Alzheimer’s dementia.
- March 2021: The National Institutes of Health (NIH) announced the launch of the Alzheimer’s disease program (AMP AD 2.0); the next version of the Accelerating Medicines Partnership (AMP). This is aimed at advancement in precision medicine research for Alzheimer’s disease.
Comprehensive Coverage U.S. Alzheimer’s Drugs Market Report
- Market Overview
- Market trends and dynamics
- Market size, share, and forecast
- Market segmentation
- Competitive landscape
- Company profiles
- Key industry developments
- Future outlook
Pricing Analysis
- Pricing strategies of leading players
- Cost of Alzheimer's drugs
- Impact of government regulations on drug prices
Import And Export Analysis
- Import and export data of Alzheimer's drugs
- Major import and export markets
- Impact of trade policies on imports and exports
Segmentation
Drug Class
- Cholinesterase Inhibitors
- NMDA Receptor Antagonist
- Combination Drugs
- Others
Application
- Disease Progression
- Symptom Management
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy & Drug Stores
- Online Pharmacy
Patent/Trademark Analysis
- Patent and trademark landscape of Alzheimer's drugs
- Analysis of key patents and trademarks
- Impact of intellectual property on market competition
U.S. Alzheimer’s Drugs Market REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2018-2032 |
| Base Year | 2023 |
| Estimated Year | 2024 |
| Forecast Period | 2024-2032 |
| Historical Period | 2018-2023 |
| Growth Rate | CAGR of 5.1% from 2018-2032 |
| Segmentation |
|
Frequently Asked Questions
Table Of Content
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Rising Awareness Regarding the Disease and its Treatment to Drive Market Growth
- 3.3. Market Restrains
- 3.3.1. High Cost of Alzheimer’s Drugs to Impede Growth Prospects
- 3.4. Market Trends
- 3.4.1. Shift Toward Development of Advance technologies for Early Detection of the Disease Identified as a Significant Market Trend
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. U.S. Alzheimer’s Drugs Market Analysis, Insights and Forecast, 2018-2030
- 5.1. Market Analysis, Insights and Forecast - by Drug Class
- 5.1.1. Cholinesterase Inhibitors
- 5.1.2. NMDA Receptor Antagonist
- 5.1.3. Combination Drugs
- 5.1.4. Others
- 5.2. Market Analysis, Insights and Forecast - by Application
- 5.2.1. Disease Progression
- 5.2.2. Symptom Management
- 5.3. Market Analysis, Insights and Forecast - by Distribution Channel
- 5.3.1. Hospital Pharmacy
- 5.3.2. Retail Pharmacy & Drug Stores
- 5.3.3. Online Pharmacy
- 5.4. Market Analysis, Insights and Forecast - by Region
- 5.4.1.
- 5.1. Market Analysis, Insights and Forecast - by Drug Class
- 6. Northeast U.S. Alzheimer’s Drugs Market Analysis, Insights and Forecast, 2018-2030
- 6.1. Market Analysis, Insights and Forecast - By Drug Class
- 6.1.1 Cholinesterase Inhibitors
- 6.1.2 NMDA Receptor Antagonist
- 6.1.3 Combination Drugs
- 6.1.4 and Others
- 6.2. Market Analysis, Insights and Forecast - By Application
- 6.2.1. Disease Progression and Symptom Management
- 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.3.1 Hospital Pharmacy
- 6.3.2 Retail Pharmacy & Drug Stores
- 6.3.3 and Online Pharmacy
- 7. Southeast U.S. Alzheimer’s Drugs Market Analysis, Insights and Forecast, 2018-2030
- 7.1. Market Analysis, Insights and Forecast - By Drug Class
- 7.1.1 Cholinesterase Inhibitors
- 7.1.2 NMDA Receptor Antagonist
- 7.1.3 Combination Drugs
- 7.1.4 and Others
- 7.2. Market Analysis, Insights and Forecast - By Application
- 7.2.1. Disease Progression and Symptom Management
- 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.3.1 Hospital Pharmacy
- 7.3.2 Retail Pharmacy & Drug Stores
- 7.3.3 and Online Pharmacy
- 8. Midwest U.S. Alzheimer’s Drugs Market Analysis, Insights and Forecast, 2018-2030
- 8.1. Market Analysis, Insights and Forecast - By Drug Class
- 8.1.1 Cholinesterase Inhibitors
- 8.1.2 NMDA Receptor Antagonist
- 8.1.3 Combination Drugs
- 8.1.4 and Others
- 8.2. Market Analysis, Insights and Forecast - By Application
- 8.2.1. Disease Progression and Symptom Management
- 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.3.1 Hospital Pharmacy
- 8.3.2 Retail Pharmacy & Drug Stores
- 8.3.3 and Online Pharmacy
- 9. Southwest U.S. Alzheimer’s Drugs Market Analysis, Insights and Forecast, 2018-2030
- 9.1. Market Analysis, Insights and Forecast - By Drug Class
- 9.1.1 Cholinesterase Inhibitors
- 9.1.2 NMDA Receptor Antagonist
- 9.1.3 Combination Drugs
- 9.1.4 and Others
- 9.2. Market Analysis, Insights and Forecast - By Application
- 9.2.1. Disease Progression and Symptom Management
- 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.3.1 Hospital Pharmacy
- 9.3.2 Retail Pharmacy & Drug Stores
- 9.3.3 and Online Pharmacy
- 10. West U.S. Alzheimer’s Drugs Market Analysis, Insights and Forecast, 2018-2030
- 10.1. Market Analysis, Insights and Forecast - By Drug Class
- 10.1.1 Cholinesterase Inhibitors
- 10.1.2 NMDA Receptor Antagonist
- 10.1.3 Combination Drugs
- 10.1.4 and Others
- 10.2. Market Analysis, Insights and Forecast - By Application
- 10.2.1. Disease Progression and Symptom Management
- 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.3.1 Hospital Pharmacy
- 10.3.2 Retail Pharmacy & Drug Stores
- 10.3.3 and Online Pharmacy
- 11. Competitive Analysis
- 11.1. Market Share Analysis 2023
- 11.2. Company Profiles
- 11.2.1 EISAI CO. LTD.
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Financials (Based on Availability)
- 11.2.2 (Japan)
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Financials (Based on Availability)
- 11.2.3 Novartis AG (Switzerland)
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Financials (Based on Availability)
- 11.2.4 Biogen Inc. (U.S.)
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Financials (Based on Availability)
- 11.2.5 H. Lundbeck A/S (Denmark)
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Financials (Based on Availability)
- 11.2.6 Otsuka Pharmaceutical Co. Ltd. (Japan)
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Financials (Based on Availability)
- 11.2.1 EISAI CO. LTD.
List of Figures
- Figure 1: U.S. Alzheimer’s Drugs Market Revenue Breakdown (undefined, %) by Product 2023 & 2031
- Figure 2: U.S. Alzheimer’s Drugs Market Value Share (%), by Drug Class 2023 & 2031
- Figure 3: U.S. Alzheimer’s Drugs Market Value Share (%), by Application 2023 & 2031
- Figure 4: U.S. Alzheimer’s Drugs Market Value Share (%), by Distribution Channel 2023 & 2031
- Figure 5: U.S. Alzheimer’s Drugs Market Share (%) by Company 2023
List of Tables
- Table 1: U.S. Alzheimer’s Drugs Market Revenue undefined Forecast, by Drug Class 2018 & 2031
- Table 2: U.S. Alzheimer’s Drugs Market Revenue undefined Forecast, by Application 2018 & 2031
- Table 3: U.S. Alzheimer’s Drugs Market Revenue undefined Forecast, by Distribution Channel 2018 & 2031
- Table 4: U.S. Alzheimer’s Drugs Market Revenue undefined Forecast, by Region 2018 & 2031
- Table 5: U.S. Alzheimer’s Drugs Market Revenue undefined Forecast, by Drug Class 2018 & 2031
- Table 6: U.S. Alzheimer’s Drugs Market Revenue undefined Forecast, by Application 2018 & 2031
- Table 7: U.S. Alzheimer’s Drugs Market Revenue undefined Forecast, by Distribution Channel 2018 & 2031
- Table 8: U.S. Alzheimer’s Drugs Market Revenue undefined Forecast, by Region 2018 & 2031
- Table 9: U.S. Alzheimer’s Drugs Market Revenue undefined Forecast, by Drug Class 2018 & 2031
- Table 10: U.S. Alzheimer’s Drugs Market Revenue undefined Forecast, by Application 2018 & 2031
- Table 11: U.S. Alzheimer’s Drugs Market Revenue undefined Forecast, by Distribution Channel 2018 & 2031
- Table 12: U.S. Alzheimer’s Drugs Market Revenue undefined Forecast, by Country 2018 & 2031
- Table 13: Northeast U.S. Alzheimer’s Drugs Market Revenue (undefined) Forecast, by Application 2018 & 2031
- Table 14: Southeast U.S. Alzheimer’s Drugs Market Revenue (undefined) Forecast, by Application 2018 & 2031
- Table 15: Midwest U.S. Alzheimer’s Drugs Market Revenue (undefined) Forecast, by Application 2018 & 2031
- Table 16: Southwest U.S. Alzheimer’s Drugs Market Revenue (undefined) Forecast, by Application 2018 & 2031
- Table 17: West U.S. Alzheimer’s Drugs Market Revenue (undefined) Forecast, by Application 2018 & 2031
- Table 18: U.S. Alzheimer’s Drugs Market Revenue undefined Forecast, by Drug Class 2018 & 2031
- Table 19: U.S. Alzheimer’s Drugs Market Revenue undefined Forecast, by Application 2018 & 2031
- Table 20: U.S. Alzheimer’s Drugs Market Revenue undefined Forecast, by Distribution Channel 2018 & 2031
- Table 21: U.S. Alzheimer’s Drugs Market Revenue undefined Forecast, by Country 2018 & 2031
| Aspects | Details |
|---|---|
| Study Period | 2018-2032 |
| Base Year | 2023 |
| Estimated Year | 2024 |
| Forecast Period | 2024-2032 |
| Historical Period | 2018-2023 |
| Growth Rate | CAGR of 5.1% from 2018-2032 |
| Segmentation |
|
STEP 1 - Identification of Relevant Samples Size from Population Database
STEP 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segemnts, product and application.
Note* : In applicable scenarios
STEP 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
STEP 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
Additionally after gathering mix and scattered data from wide range of sources, data is triangull- ated and correlated to come up with estimated figures which are further validated through primary mediums, or industry experts, opinion leader.
About Market Research Forecast
MR Forecast provides premium market intelligence on deep technologies that can cause a high level of disruption in the market within the next few years. When it comes to doing market viability analyses for technologies at very early phases of development, MR Forecast is second to none. What sets us apart is our set of market estimates based on secondary research data, which in turn gets validated through primary research by key companies in the target market and other stakeholders. It only covers technologies pertaining to Healthcare, IT, big data analysis, block chain technology, Artificial Intelligence (AI), Machine Learning (ML), Internet of Things (IoT), Energy & Power, Automobile, Agriculture, Electronics, Chemical & Materials, Machinery & Equipment's, Consumer Goods, and many others at MR Forecast. Market: The market section introduces the industry to readers, including an overview, business dynamics, competitive benchmarking, and firms' profiles. This enables readers to make decisions on market entry, expansion, and exit in certain nations, regions, or worldwide. Application: We give painstaking attention to the study of every product and technology, along with its use case and user categories, under our research solutions. From here on, the process delivers accurate market estimates and forecasts apart from the best and most meaningful insights.
Products generically come under this phrase and may imply any number of goods, components, materials, technology, or any combination thereof. Any business that wants to push an innovative agenda needs data on product definitions, pricing analysis, benchmarking and roadmaps on technology, demand analysis, and patents. Our research papers contain all that and much more in a depth that makes them incredibly actionable. Products broadly encompass a wide range of goods, components, materials, technologies, or any combination thereof. For businesses aiming to advance an innovative agenda, access to comprehensive data on product definitions, pricing analysis, benchmarking, technological roadmaps, demand analysis, and patents is essential. Our research papers provide in-depth insights into these areas and more, equipping organizations with actionable information that can drive strategic decision-making and enhance competitive positioning in the market.
